Laboratory Corporation of America, 1904 TW Alexander Drive, RTP, NC 27709, United States.
Laboratory Corporation of America, 3400 Computer Drive, Westborough, MA 01581, United States.
Cancer Genet. 2023 Jun;274-275:33-40. doi: 10.1016/j.cancergen.2023.02.003. Epub 2023 Mar 11.
A cohort of leukemia cases is presented with ancillary testing that includes microarray studies, karyotyping, FISH, and RNA sequencing to illustrate clonal evolution. Common evolution etiology with each case is apparent homologous mitotic recombination (HMR). The cohort includes: four cases of Pre B-cell acute lymphoblastic leukemia (B-ALL) with a single translocation derivative (19)t(1;19)(q23.3;p13.3), an acute myelogenous leukemia (AML) case with a paracentric inversion of 11q13.3q23 in both homologues confirmed as a rare KMT2A-MAML2 gene fusion, and a transplant patient in AML relapse with a t(6;11)(6q27;q23) and evolution to an additional derivative 6 chromosome. The PBX1-TCF3 fusion in the t(1;19) B-ALL subgroup has long been associated with clones that show either the balanced translocation (∼25%) or the unbalanced single derivative 19 (∼75%). Evidence from the CMAs and FISH is consistent with HMR initiating at either the PBX1 translocation breakpoint or at a more proximal long arm site that mediates the evolution to the unbalanced form. This is contrary to the previous assumptions of either nondisjunction duplication of the normal homologue with loss of the translocation derivative 1 or an original trisomy 1 that loses the translocation derivative 1. Relapse from an unrelated transplant donor created unique allele dosage ratios in the microarray of the AML patient with the t(6;11) KMT2A-AFDN fusion. An HMR-based evolution initiation site proximal to the 6q27 AFDN fusion gene is evident in the microarray of chromosome 6, the known oncogenic fusion derivative. The HMR selection driver in both AML cases is very likely associated with the DNA doubling of the oncogenic fusions in 6q and 11q, respectively. Since the oncogenic derivatives in the 1;19 cases are clearly the retained derivative 19, selection for the HMR clonal evolution in 1q is apparently based on the known proliferative advantage of extra copies of 1q in B-ALL and other malignancies. Although selection-based HMR can effectively initiate at any site proximal to a driver gene fusion, it appears that the translocation breaksite is common for many translocations. In addition, evidence from HMR evolution related distal 11q mutations, numerous unbalanced CCND1/IGH translocations, and the double MAML2/KMT2A presented in this study suggest that a recombinatorial "hot spot" exists near the CCND1 gene in many rearrangements or mutations within 11q.
呈现了一组白血病病例,辅助检测包括微阵列研究、核型分析、FISH 和 RNA 测序,以说明克隆进化。每个病例的共同进化病因是明显的同源有丝分裂重组 (HMR)。该队列包括:四个前 B 细胞急性淋巴细胞白血病 (B-ALL) 病例,均有单个易位衍生体 (19)t(1;19)(q23.3;p13.3),一个急性髓系白血病 (AML) 病例,两个同源体中均存在 11q13.3q23 的旁中心倒位,被确认为罕见的 KMT2A-MAML2 基因融合,以及一个 AML 复发的移植患者,有 t(6;11)(6q27;q23),并进化为另一个衍生 6 号染色体。在 t(1;19) B-ALL 亚组中, PBX1-TCF3 融合一直与表现出平衡易位(约 25%)或不平衡单衍生体 19(约 75%)的克隆有关。CMAs 和 FISH 的证据一致表明,HMR 起始于 PBX1 易位断点或介导向不平衡形式进化的更近的长臂位点。这与之前的假设相反,即正常同源体的非分离复制导致丢失易位衍生体 1,或者原始三体性 1 丢失易位衍生体 1。来自无关移植供体的复发在 AML 患者的 t(6;11) KMT2A-AFDN 融合的微阵列中创建了独特的等位基因剂量比。在染色体 6 的微阵列中,在已知的致癌融合衍生物中,可见到与 HMR 相关的进化起始点近端到 6q27 AFDN 融合基因。两个 AML 病例中的 HMR 选择驱动因素很可能与 6q 和 11q 中的致癌融合的 DNA 加倍有关。由于 1;19 病例中的致癌衍生物显然是保留的衍生体 19,因此 1q 中 HMR 克隆进化的选择显然基于 B-ALL 和其他恶性肿瘤中 1q 额外拷贝的已知增殖优势。虽然基于选择的 HMR 可以有效地在驱动基因融合的任何近端位点起始,但易位断点似乎是许多易位的常见部位。此外,本研究中与 HMR 进化相关的远端 11q 突变、大量不平衡的 CCND1/IGH 易位以及双重 MAML2/KMT2A 的证据表明,在许多重排或 11q 内突变中,CCND1 基因附近存在一个重组“热点”。